medigraphic.com
ISSN 0210-5187 (Electronic)

2006, Number 5

<< Back Next >>

Med Cutan Iber Lat Am 2006; 34 (5)

Hydroxyurea induced cutaneous lupus erythematosus

De Kok EM, Giansante E, Sciamanna E, Oliver M

Language: Spanish
References: 20
Page: 244-246
PDF size: 171.66 Kb.


ABSTRACT

Lupus erythematosus is a multisystem disease of unknown origin characterized by the production of numerous diverse types of autoantibodies that, through immune mechanisms in various tissues, cause several combinations of clinical signs, symptoms, and laboratory abnormalities. Many drugs have been reported to cause a syndrome similar to systemic lupus erythematosus. We present a case of hydroxyurea-induced lupus and review the features of this entity.


REFERENCES

  1. 1.Pérez-Alfonzo R, Giansante E. Lupus eritematoso cutáneo. En: Rondón Lugo A. Pautas diagnósticas y terapéuticas. Tipografía Olimpia 2001:187-88.

  2. 2.Iglesias L, Guerra A. Lupus inducido por fármacos. En: Iglesias L, Guerra A, Ortiz P. Tratado de dermatología. McGraw-Hill Inter-americana de España. 2004:377.

  3. 3.Chabner B, Allegra C, Curt G, Calabresi P. Fármacos antineoplásicos. En: Goodman & Gilman. Las Bases Farmacológicas de la Terapéutica. McGraw-Hill Interamericana. 1999:1350-51.

  4. Crocuson AN, Magro CM, Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 1999;17(3):537-60.

  5. 5.Susser WS, Whitaker-Worth DL, Grant-Kels JM, Mucocutaneous reactions to chemotherapy, J Am Acad Dermatol 1999;40(3):367-98.

  6. Litt J. The Pocketbook of Dug Euptions and Interactions. Parthenon Publishing. 2001:208.

  7. Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch Dermatol 1975;3:183-87.

  8. 8.Majumdar G, Heard SE, Slater NG. Reversible hyperpigmentation associated with high dose hydroxyurea. BMJ 1990;300:1468.

  9. Hendrix JD, Greer KE. Cutaneous hyperpig-mentation caused by systemic drugs. Int J Dermatol 1992;31:458-66.

  10. Gropper CA, Don PC, Sadjadi MM. Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera. Int J Dermatol 1993;32:731-33.

  11. De Montalembert M, Begue P, Bernaudin F, Thuret I, Bachir D, Micheau M, Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Arch Dis Child 1999;81(5):437-9.

  12. 12.Layton AM, Cotterill JA, Tomlinson IW. Hydroxyurea-induced lupus erythematosus. Br J Dermatol 1994;130(5):687-8.

  13. 13.Layton AM, Cotterill JA. Immunological changes in hydroxyurea-induced collagen disease. Br J Dermatol 1994;131(4):581-2.

  14. Rubin RL. Drug-Induced lupus. En: Wallace DJ, Hahn BH (eds.): Dubois Lupus Erythrematosus, 5th ed. Philadelphia: Williams & Wilkins. 1997:871-901.

  15. Rubin RL. Etiology and mechanisms of drug-induced lupus. Curr Opin Rheumatol 1999; 11(5):357-63.

  16. Rubin RL, Bell SA, Bulingame RW. Autoanti-cuerpos associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992;90:165.

  17. 17.Yun RL, Johnson KJ, Richardson BC. New concepts in the patogenesis of drug-induced lupus. Lab Invest 1995;73:746.

  18. 18.Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxicproducts by activated neutrophils. Science 1994;266:810.

  19. 19.McKinnon RA, Nebert DW. Posible role of cytochrome P450 in lupus erythematosus and related disorders. Lupus 1004;3:473.

  20. 20.Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doira A. Drug-induced lupus erythematosus. Autoimmunity 2005;38(7): 507-18.




2020     |     www.medigraphic.com